Table 3.
Cox proportional hazards model of prognostic factors for recurrence-free survival in 210 patients with hepatocellular carcinoma after curative hepatectomy
| Variable |
Univariate analysis |
Multivariate analysis |
||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Age(yr), ≥ 60 vs < 60 | 1.319 (0.859-2.027) | 0.206 | ||
| Gender, male vs female | 0.855 (0.458-1.594) | 0.621 | ||
| Liver cirrhosis: yes vs no | 1.316 (0.831-2.086) | 0.242 | ||
| ALT (U/L), > 75 vs ≤ 75 | 1.709 (1.096-2.665) | 0.018 | 1.510 (0.960-2.375) | 0.074 |
| Total bilirubin (μmol/L), > 34 vs ≤ 34 | 1.471 (0.715-3.023) | 0.294 | ||
| Albumin (g/L), ≥ 35 vs < 35 | 0.279 (0.160-0.485) | < 0.001 | ||
| ALP (U/L), > 100 vs ≤ 100 | 1.506 (0.964-2.354) | 0.072 | ||
| AFP (ng/dL), > 400 vs ≤ 400 | 0.934 (0.636-1.373) | 0.730 | ||
| Tumor size (cm), > 5 vs ≤ 5 | 2.020 (1.354-3.012) | 0.001 | ||
| Tumor number, multiple vs single | 1.599 (0.953-2.684) | 0.075 | ||
| Portal vein thrombus, yes vs no | 2.282 (1.150-4.529) | 0.018 | ||
| Microvascular invasion, yes vs no | 1.185 (0.742-1.892) | 0.478 | ||
| Histological differentiation, poor vs well and moderate | 2.628 (1.561-4.425) | < 0.001 | 2.610 (1.542-4.416) | < 0.001 |
| BCLC stage, B + C vs 0 + A | 1.724 (1.180-2.520) | 0.005 | 1.645 (1.124-2.409) | 0.010 |
| Preoperative LMR, > 3.23 vs ≤ 3.23 | 0.601 (0.410-0.883) | 0.009 | 0.584 (0.398-0.859) | 0.006 |
AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BCLC: Barcelona Clinic Liver Cancer; LMR: Lymphocyte-to-monocyte ratio.